Kyle Holen

Kyle Holen is the Head of Development for Oncology and Therapeutics at Moderna since September 2022. Prior to this, Kyle Holen held various leadership roles at AbbVie from February 2012 to September 2022, including Vice President for Therapeutic Areas in General Medicine and Infectious Diseases, and Vice President of the Development Design Center, where guidance was provided to clinical teams utilizing big data for trial design. Additional responsibilities included serving as Executive Medical Director, focusing on drug development for heme/onc assets, and Senior Project Leader, overseeing the development of oncology assets from IND to BLA/NDA. Earlier experience includes Medical Director at Abbott and Associate Professor at the University of Wisconsin-Madison, where leadership in oncology clinical trials and fellowship direction was emphasized. Kyle Holen's educational background includes a Medical Degree from Columbia University, residency in Internal Medicine at New York Presbyterian Hospital, and a fellowship in Hematology/Oncology at Memorial Sloan-Kettering Cancer Center.